Oxidative stress is a consequence of up-regulation of pro-oxidant enzyme-induced reactive oxygen species (ROS) production and concomitant depletion of antioxidants. Elevated levels of ROS act as an intermediate and are the common denominator for various diseases including diabetes-associated macro-/micro-vascular complications and hypertension. A range of enzymes are capable of generating ROS, but the pro-oxidant enzyme family, nicotinamide adenine dinucleotide phosphate (NADPH) oxidases (NOXs), are the only enzymes known to be solely dedicated to ROS generation in the vascular tissues, kidney, aortas and eyes. While there is convincing evidence for a role of NOX1 in vascular and eye disease and for NOX4 in renal injury, the role of NOX5 in disease is less clear. Although NOX5 is highly up-regulated in humans in disease, it is absent in rodents. Thus, so far it has not been possible to study NOX5 in traditional mouse or rat models of disease. In the present review, we summarize and critically analyse the emerging evidence for a pathophysiological role of NOX5 in disease including the expression, regulation and molecular and cellular mechanisms which have been demonstrated to be involved in NOX5 activation.
Introduction
Over the last few years, a significant body of evidence has accumulated with regard to pro-oxidant NADPH oxidase (NOX) enzymes and this has facilitated a better understanding of reactive oxygen species (ROS) pathophysiology and the contribution of individual NOX isoforms in the development and progression of cardiovascular diseases including diabetes-associated complications [1] [2] [3] [4] [5] [6] . At baseline, most NOX isoforms have very low or no constitutive activity but their expression at the gene or protein level can be increased in disease states such as hypertension and diabetes. In these situations, the activation of NOX isoforms generates enhanced levels of ROS which surpasses the handling capacity of the endogenous antioxidant system, thus leading to increased oxidative stress and ultimately tissue injury. On the one hand ROS regulate physiological cell survival and differentiation, vessel contraction and relaxation as well as blood pressure, while on the other hand, NOX-derived ROS are associated with inflammation which is closely linked to atherosclerosis, hypertension, diabetes and hypercholesterolaemia [7] .
So far seven known isoforms of the NOX family have been identified which include NOX2 (formerly termed gp91phox), NOX1, NOX3, NOX4 (formerly termed RENOX), NOX5 and dual oxidases (DUOX1 and DUOX2) [5] . The similarities among these NOX enzymes are that they utilize NADPH as substrate to reduce molecular oxygen to produce superoxide (O 2 − ), which is then converted to other types of ROS [8] . NOX isoforms share common structural properties which include the NADPH-binding site at the C-terminus, the flavin adenine dinucleotide (FAD)-binding region in proximity of the C-terminal transmembrane domain, six conserved transmembrane domains and four conserved haem-binding histidines [9] . Among these isoforms, the expression of NOX1, NOX2, NOX4 and NOX5 has been identified in the target organs of diabetic complications and hypertension, including blood vessels, retina, kidney and peripheral nerves [5, 9] . While the contribution of NOX1, NOX2 and NOX4 has been widely studied in the macro-and micro-vascular complication of diabetes including nephropathy [6, [10] [11] [12] , retinopathy [13, 14] , atherosclerosis [3, 5] and hypertension [3, 5, 15] , very little is known about the role of NOX5 in these disease states. This is primarily due to the fact that NOX5 is absent from the rat and mouse genome and rodents represent the most established experimental models for the study of disease processes including diabetes and hypertension. Importantly, NOX5 is found to be up-regulated in disease states in humans making it an important research target in the various diseases. The main focus of this review is to outline recent advances in our knowledge and understanding about the pathophysiological role of NOX5 in vascular disease including diabetes and hypertension.
Modulation of NOX5 activity Activation
It is hypothesized that the increase in intracellular calcium by hyperglycaemia and angiotensin II (AngII) and the consequent binding of calcium to NOX5 cause its activation [4, 16] . Unlike other NOX isoforms, NOX5 has the ability to bind and be activated by intracellular calcium directly [17] and its function to produce ROS is regulated by intracellular calcium mobilization and influx [18] , and phosphorylation [17, [19] [20] [21] [22] as illustrated in Figure 1 . The N-terminal domain of NOX5 has four calcium-binding EF-hand motifs, although the binding of three calcium ions is hypothesized to be enough for activation of the enzyme [23] . Unlike other NOX isoforms, NOX5 does not require the binding of other cytosolic subunits for the activation [24] . Similar to nitric oxide (NO) synthase (although with a different amino acid sequence), NOX5 contains a binding site for the calcium-modulated/binding protein calmodulin at its C-terminal domain. Once calmodulin is bound, NOX5 shows increased sensitivity to calcium in that it is activated at lower intracellular calcium levels [25] . In addition, elevation of intracellular calcium causes a change in the conformation of the EF-hands at the N-terminus which promotes an interaction with the C-terminus [17] .
Several pro-inflammatory cytokines, chemokines and growth factors have been described to up-regulate NOX5 expression, including peptide hormones such as AngII and endothelin 1 (ET1) [26] [27] [28] (also see below in NOX5 and complications of diabetes in the kidney). The non-receptor tyrosine kinase, c-Abl, can also amplify NOX5 activation in response to increased intracellular calcium influx caused by peroxide [29] .
NOX5 activity can also be up-regulated by direct phosphorylation; however, molecular mechanisms by which this occurs remain poorly understood. It has been suggested that the phosphorylation of NOX5 at key residues facilitates enzyme activation at lower levels of intracellular calcium which may lead to greater activation of the enzyme. Phosphorylation of NOX5 occurs via a number of mechanisms. Calcium/calmodulin-dependent kinase II can activate NOX5 via direct phosphorylation [20] . However, the largest body of evidence in regards to the phosphorylation of NOX5 relates to the mitogen-activated protein kinase (MAPK) and protein kinase C (PKC) [20] . Phosphorylation of the C-terminus of NOX5 by PKC (mainly PKC-α) promotes NOX5 activation at lower calcium levels [19, 30, 31] . The PKC stimulator phorbol 12-myristate 13-acetate (PMA) caused activation of NOX5 which was independent from changes in intracellular calcium [21, 30] . A recent study reported that PKC-α directly mediates NOX5 phosphorylation and activity, while PKC-ε and PKC-δ modulate NOX5-derived superoxide production through indirect mechanisms [19, 32] . These findings could represent a feedback loop whereby NOX5 and certain PKC isoforms interact in a bidirectional manner to amplify tissue injury. Of importance for diabetes, exposure of endothelial cells (ECs) to high glucose has also been found to increase PKC-α activation and NOX5-derived superoxide [19] .
Inhibition
NO is a potent inhibitor of NOX enzymes, including NOX5 [33] . Qian and colleagues showed that endogenous NO suppresses basal and stimulated NOX5 superoxide production (assessed by L-012 and lucigenin superoxide) in transfected cells with S-nitrosylation of NOX5 by NO being essential to its inhibition [33] . It has also been suggested that oxidation of calcium-binding sites within the N-terminal of NOX5 may be involved in its inactivation [23] . Other mechanisms shown to lower intracellular calcium are also expected to decrease ROS generation via this isoform. Other regulators of NOX5 activity include chaperones such as Hsp90, calmodulin and caveolin-1 [17, 28, 32, [34] [35] [36] .
NOX5: splice variants and localization
NOX5 is the most recently identified member of the NOX family after NOX4. Despite sharing significant homology to NOX1 and NOX2, NOX5 is structurally and functionally distinct from other NOX isoforms in ways which include alternative splicing, transcriptional regulation, enzymatic control mechanisms, tissue distribution and intracellular trafficking [37] . NOX5 has been reported to produce both superoxide and hydrogen peroxide [21, 38] .
The human NOX5 gene is located on chromosome 15 and six splice variants of this gene have been identified including NOX5-L (NOX5α, NOX5β, NOX5γ , NOX5δ), a truncated variant NOX5ε (also known as NOX5-S) and NOX5ζ [34] . The basic differences in these splice variants of NOX5 are modifications within the N-terminal domain, which is important for calcium binding and catalytic activity. NOX5-S lacks the NH2-terminal calmodulin-like domain with the four calcium-binding EF-hands [39] . Based on homology to the other NOX5 splice variants, NOX5ζ is thought to be active; however, its activity remains to be evaluated [34] . Among these splice variants of NOX5, NOX5α and β are the functional ROS-generating proteins [19] as illustrated in Figure 1 .
All splice variants of NOX5 are expressed in endothelial and vascular smooth muscle cells (VSMCs); NOX5α and β are the most abundant and functional isoforms expressed in cells [24, 40] , but vary in degree of expression. The individual splice variants are tissue specific, e.g. NOX5α is highly expressed in the spleen, NOX5β in the testis [38] and NOX5-S in the oesophageal cancer cells [41] . Furthermore, subcellular fractionation studies demonstrated that NOX5 is expressed primarily within intracellular membranes and is predominantly localized in the perinuclear area with an extensive network of branching tubules which project into the cytosol and to a lesser extent in the plasma membrane, Golgi apparatus, mitochondria and endoplasmic reticulum (ER) [30] . NOX5β, δ and ε are reported to be present in the ER of microvascular ECs [24] . However, the functional significance of NOX5 localization to detergent-insoluble microdomains of the ER is not known. The dominant ROS species generated by NOX5 is superoxide, which is one of the ROS with slow reactivity. ROS targets range from molecular targets including DNA to proteins and lipids. Within proteins, cysteine residues and Fe-S clusters are very prone to oxidative modification [42] . This can affect protein structure and function as well as protein-protein interactions [43] . At this stage, the precise molecular and biological local and global targets of NOX5 including its splice variants and their derived ROS are not known.
NOX5 and complications of diabetes In the kidney
A growing number of studies show that within the kidney, NOX1, NOX2, NOX4 and NOX5 isoforms are expressed in mesangial cells, VSMCs, ECs, podocytes, tubular epithelial cells and interstitial fibroblasts [2, 44] . While the evidence for a role of NOX4-derived ROS-mediated renal injury is convincing, the functional significance of NOX5 in chronic kidney disease including nephropathy remains poorly understood. A study by Holterman et al. [4] however has shown increased expression of NOX5β in human kidney biopsies from diabetic patients. Since NOX5 is absent in mouse genome, the authors studied NOX5 transgenic mice with selective expression of human NOX5 in podocytes in the presence or absence of diabetes. Interestingly, they found increased ROS levels with subsequent increased glomerular injury and tubulointerstitial fibrosis as well as increased albuminuria in NOX5 transgenic mice which was further exacerbated in the presence of diabetes [4] . In addition, they reported that high glucose or AngII stimulates NOX5-dependent ROS production in human or mouse podocytes [4] . Moreover, Holterman et al. [4] also found podocyte foot process effacement in diabetic transgenic mice expressing NOX5 in podocytes suggesting the deleterious effect of NOX5 in podocyte damage and development of albuminuria.
Our own unpublished data show that silencing of Nox5 using a lentiviral shRNA approach attenuates the high glucose-induced increase in markers of fibrosis (collagen IV and fibronectin) and inflammation (MCP-1) in cultured human podocytes. Within the kidney, alterations in the function and structure of mesangial and ECs are equally important in diabetic nephropathy. Therefore, there is interest in evaluating the role of NOX5 in transgenic mice which express NOX5β selectively in either mesangial or ECs in the absence and presence of diabetes. These studies will provide additional information about the pathophysiological role of NOX5 in specific cell types and diseases. However, the clinical relevance of such transgenic approaches remains to be fully explored.
In the eye
To date, there is a lack of experimental evidence regarding the role of NOX5 in diabetic retinopathy. NOX5 in human retinal cells, bovine retinal ECs and pericytes all express NOX5, however [14] , indicating that NOX5 may be relevant to retinal vascular pathology [45] . Indeed, recent studies using human vascular cells have shown that NOX5 influences EC proliferation, suggesting that NOX5 may be important in neovascularization and vascular leakage, the pathological events associated with vision loss and blindness [14] . Mechanism-based studies are required to evaluate the pathophysiological significance of NOX5 expression and activation in the eye using experimental models of retinal pathology.
In the vasculature
Among the seven NOX isoforms discovered so far, four isoforms are expressed in the vasculature (NOX1, NOX2, NOX4 and NOX5), each with a unique expression pattern, mechanism of activation and effect on the vasculature [7] . NOX isoforms (including NOX5) have been described in ECs, VSMCs, adventitial fibroblasts, and in several leucocyte subsets [39, 46, 47] . Cultured human aortic smooth muscle cells (ASMCs) express four different isoforms of NOX5 (α, β, γ and δ) which regulate specific pathways [40] . Though overexpression of either NOX5β or NOX5ε is reported to enhance ROS levels, the addition of a calcium ionophore enhanced only ROS generated by NOX5β but not NOX5ε [48] . Both NOX5-L and NOX5-S promote proliferation and angiogenesis in vitro in an EC line [48] . Interestingly, NOX5ε was not found in either healthy or diseased coronary arteries [49] , while NOX5β is enhanced in coronary arteries of patients with coronary artery disease (CAD) [48, 49] . Although all NOX5 variants are functionally active in human ECs [24] , it has been suggested that NOX5α and β are ROS-producing enzymes and that NOX5ε may be a negative regulator of NOX5 [34] . The fact that NOX5 exists as different splice variants which differ in location, modulation and activation is suggestive of the complex role of NOX5 in diverse signalling pathways in the vasculature [40] . Indeed, it is also reported that several SNPs which encode non-functional variants of NOX5 are found at relatively high frequency in humans suggesting the possible existence of humans lacking a functional NOX5 [50] .
NOX5 is implicated in the proliferation of VSMCs which is an important step underlying vascular disorders such as atherosclerosis [40] . NOX5-derived ROS mediates platelet-derived growth factor-mediated proliferation of human ASMCs via the JAK/STAT pathway [40] . Additionally, NOX5 also contributes to the formation of capillary-like structures. Overexpression of NOX5 enhances endothelial proliferation and tubule formation, while depletion of NOX5 reduces thrombin-stimulated tube formation [24] .
Expression of adhesion molecules in the endothelium is an important step during atherosclerotic lesion formation and facilitates leucocyte recruitment not only to the endothelium but also to the adventitia and outer media [51] . The expression of vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1) as well as P-and E-selectins is also activated by NOX5, and is thought to be mediated partly via the redox-regulated NF-κB site within the promoter region [51] . Vasoactive agents such as AngII and ET1 play an important pathophysiological role in endothelial dysfunction and vascular injury [26] . Montezano et al. [26] reported that NOX5 in human ECs is regulated by AngII and ET1 through calcium and calmodulin-sensitive processes. Furthermore, recent studies have suggested a possible link between NOX5 and the chemokine Fractalkine (CX3CL1) [51] . Rius et al. [52] observed that NOX5 played a major role in AngII-induced increased CX3CL1 expression in human umbilical arterial ECs.
The expression of different NOX isoforms in atherosclerotic lesions varies depending on the stage of plaque development [49] . NOX1, NOX2, NOX4 and NOX5 are increased in atherosclerotic plaques of CAD patients; however, it has been postulated that NOX5 accounts for most of the increased ROS observed in atherosclerosis [48] . In the first study describing the presence of NOX5 in human vasculature, Guzik et al. [49] studied coronary arteries from patients undergoing cardiac transplantation with or without CAD. These authors observed that while NOX5 was expressed in the healthy endothelium in coronary arteries and ECs in humans, its expression was greatly enhanced in the endothelium of atherosclerotic aortas. Nox5 mRNA, protein and calcium-dependent NOX activity were significantly enhanced in the arteries of patients with CAD [49] . In the same study, the authors observed that calcium-dependent NOX activity increased 7-fold in comparison with only a 2.5-fold increase in calcium-independent NOX activity. NOX5 was found to be expressed in the ECs of early-stage lesions, and in the VSMCs of the sub-intimal region in moderately advanced lesions. In complex advanced lesions, NOX5 was extensively present in the whole lesion [49] . Recently, Manea et al. [39] reported that NOX5 is constitutively expressed in human monocytes and CD14 + cells, and that NOX5 expression is increased in response to IFN-γ or oxidized LDL, both known to stimulate inflammation and ROS production. Importantly, the authors also observed that NOX5 was extensively present in the CD68 + macrophage-rich areas in human carotid artery atherosclerotic plaques [39] .
Platelets play a critical role in the pathophysiology of atherosclerosis [53] . Vara et al. [54] observed that 2-acetylphenothiazine, a novel NOX inhibitor, impairs collagen-dependent thrombus formation in a GPVI-dependent manner. Additionally, the authors observed that NOX1 and NOX2 are expressed in human platelets while NOX4 and NOX5 are absent [54] . In contrast, Bartimoccia et al. [55] recently reported the expression of NOX5 in platelets from patients with chronic granulomatous disease.
Lob et al. [56] reported that calcium channel antagonists decrease ROS in human ECs. Guzik et al. [49] speculated that the increased expression of the calcium-dependent NOX5 isoform may be responsible for the benefits afforded by calcium channel antagonists in CAD. It is indeed possible that these drugs reduce NOX5 activation in cells with L-type calcium channels, including VSMCs in lesions. Vasodilators which reduce intracellular calcium may exert a similar activity [49] . However, the utility of calcium antagonists such as amlodipine as NOX5 specific inhibitors is unlikely because ECs lack voltage-dependent calcium channels [57] . Thus, the specific role for the recently described human isoform, NOX5 and its splice variants in the vasculature is in need of further study.
NOX5 and hypertension

In the kidney
Hypertension is a common risk factor for the development of kidney disease and is further accelerated in diabetic patients [58] . It has been postulated that both conditions are associated with increased generation of ROS. NOX isoforms in the kidney have previously been linked to the occurrence of hypertension (for review see [59] ), however only little has been published on the role of NOX5 in the pathogenesis of hypertension. Yu and colleagues investigated NOX isoforms in isolated renal proximal tubules from normotensive and hypertensive patients with changes in NOX5 protein expression being shown to be the most elevated of all the isoforms [60] . Protein expression of NOX5 in cells from hypertensive patients was 5-fold higher than in cells from normotensive patients. Similarly, gene expression for Nox5 was 3-4-fold greater. Silencing of Nox5 in proximal tubular cells from hypertensive patients resulted in a significant attenuation in ROS generation (assessed by lucigenin) [60] .
NOX5 may also play a role in pathogenesis of hypertension via NOX5 expression in the glomerulus. Transgenic mice which express human NOX5 specifically in podocytes were found to be hypertensive and developed albuminuria in association with effacement of podocyte foot processes [4] . Thus, NOX5-generated ROS in the podocyte may be a critical factor in hypertension.
In the vasculature
As in the kidney, NOX-derived ROS have also been implicated in the pathogenesis of hypertensive vascular disease (see [61, 62] for overall review of NOX isoforms). Chen and colleagues have shown that expression of the regulatory peptide caveloin-1 is reduced in pulmonary arteries in three different experimental models of pulmonary artery hypertension [63] . They also report that in vitro caveolin-1 can inhibit the activity of NOX isoforms, specifically by binding to NOX5 and NOX2. The authors also note that calmodulin can negatively affect caveolin-1 binding to NOX5 and its binding is regulated by calcium levels. Thus, a hypertension-mediated decrease in expression of caveolin-1 may lead to a disinhibition and subsequent activation of NOX5.
Epigenetic mechanisms have also been shown to play a role in NOX isoform gene expression in hypertension. Another study by Chen and colleagues reports that multiple isoforms of histone deacetylases are up-regulated in pulmonary arteries in a rat model of pulmonary hypertension. Inhibition of histone deacetylases by scriptaid or suberoylanilide hydroxamic acid in transfected cells potently suppressed Nox1, 2, 4 and 5 gene expression in vitro [35] .
While it is clear than NOX isoforms are implicitly involved in the pathogenesis of hypertensive-related cardiovascular disease, investigation of the specific role of NOX5 in hypertensive vascular disease is ongoing.
In the brain
Interestingly, oxidative stress is suggested to play a role in the centrally driven sympathetic activation which occurs in hypertension [64] . Superoxide generated at least in part through NOX2 in the autonomic paraventricular nucleus of the hypothalamus has been shown to contribute to AngII-mediated hypertension [65] . Furthermore, gene expression of Nox2 and Nox4 has been found to be up-regulated in the paraventricular nucleus of spontaneously hypertensive rats as compared with normotensive Wistar-Kyoto controls [66] . Adenoviral silencing of paraventricular Nox2 or Nox4 has also been shown to attenuate salt/aldosterone-induced hypertension in mice [67] . While NOX5 has been found in the brain [68] , its role in the pathogenesis of hypertension remains unknown due to the absence of NOX5 in rats and mice, which are the most widely used neurological models.
Pharmacological NOX inhibitors
Currently, there is no NOX5 specific inhibitor available. A NOX5-specific inhibitor would be a highly useful tool for in-depth studies on NOX5 [48] . Several non-specific NOX inhibitors, such as apocynin, DPI, celastrol, VAS3947 as well as the first-in class specific NOX1/4 inhibitor, GKT137831 also inhibit NOX5 to a lesser degree [48] . However, as NOX5 contains domains which are not present in other NOX isoforms, the development of a targeted small molecule NOX5 inhibitor is possible [48] . Melittin, a model peptide for calmodulin targets, very potently inhibited NOX5 activity (K m = 101 nM) by directly binding to the EF-hand domains in a cell-free assay [17] . Peptides which specifically target the regulatory calcium-binding domain of NOX5 dose-dependently inhibited ROS (IC 50 = 30 μM) [22] . A recently developed specific NOX inhibitor, GKT137831 which blocks NOX1 and NOX4 and to a lesser degree NOX5 is currently in clinical evaluation for diabetic nephropathy [69, 70] .
NOX5 and cancer
NOX-dependent increased levels of ROS has been shown to contribute in the initiation of numerous cancer types along with the increase in proliferation and growth of cancerous cells [71] . Varying levels of NOX5 expression have been found in a number of cancers or cancer cell lines including breast, endometrial, liver, thyroid, melanoma, prostate, pancreatic, hairy cell leukaemia and oesophageal cancer [41, [72] [73] [74] [75] . A study by Höll et al. [76] showed that knockdown of NOX5 in prostate cancer cell lines (PC-3, LNCaP) resulted in decreased proliferation and increased apoptotic cell death of PC cells by modulating the activity and expression of PKC-ζ and JNK1/3, suggesting the potential role of NOX5 in prostate cancer as a regulator of epithelial cells proliferation and apoptosis. Another study has found increased levels of NOX5 protein in chronic B-cell malignancy, specifically in circulating hairy cells, and no expression of NOX5 in malignant cells of chronic lymphocytic leukaemia, suggesting cell specific variations in NOX5 expression [74] . The pre-clinical evidence suggests that NOX5 is a potential regulator of cell proliferation and apoptosis in various cancerous cells, and therefore inhibition of NOX5 could be a useful therapeutical target in alleviating the burden of cancers.
The rabbit as a new model for the study of NOX5
Several groups, including ours, are now evaluating the role of NOX5 using genetically modified transgenic and knockin mouse models. The presence of NOX5 in the rabbit genome, unlike the rodent genome, coupled with advances in genome editing such as CRISPR/Cas9 may help to further understand the importance and functional relevance of NOX5 under pathophysiological conditions in various disease states including cardiovascular disease [35] . Recently, the mRNA and protein sequence of rabbit NOX5 have been studied with identification of the various splice variants of NOX5 and their functions in response to both calcium-dependent and phosphorylation-dependent signals [35] . Furthermore, this study examined the effect of rabbit Nox5 silencing using four different miRNAs and found reduction in NOX5 protein expression as well as attenuation in superoxide production. Another study has suggested that the presence of NOX5 in the rabbit may be a useful genetic marker for studying the taxonomic position of lagomorphs and the Glires classification [77] . Of note, activation and expression of NOX5 appear very similar between humans and the rabbit. Thus, the rabbit may become an important experimental model and tool for determining the role of NOX5 in the pathophysiology of diseases.
Summary and conclusions
Unlike the other NOX isoforms, the functional significance of NOX5 in diseases is poorly understood and this is mainly due to the lack of NOX5 in the rodent genome and thus unavailability of conventional mouse or rat models. However, the introduction of advanced approaches using transgenic or knockin mice expressing human NOX5 or rabbit models which endogenously express NOX5 have facilitated exploration of the role of NOX5 in various disease processes including in hypertension and diabetic complications. Further studies are required to identify the functional significance of NOX5 under pathological conditions in various diseases including cardiovascular disease, hypertension and diabetes.
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